<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">persmed</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал персонализированной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal for Personalized Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2782-3806</issn><issn pub-type="epub">2782-3814</issn><publisher><publisher-name>ФОНД АЛМАЗОВА</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/2782-3806-2023-3-4-59-65</article-id><article-id custom-type="elpub" pub-id-type="custom">persmed-185</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНФЕКЦИОННЫЕ БОЛЕЗНИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INFECTIOUS DISEASES</subject></subj-group></article-categories><title-group><article-title>Зависимость тяжести течения  СOVID-19 от вирусной нагрузки у госпитализированных пациентов</article-title><trans-title-group xml:lang="en"><trans-title>Dependence of the severity of the course of  COVID-19 on viral load in hospitalized patients</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голодяева</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Golodyaeva</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Голодяева Мария Владимировна - старший биолог  централизованной диагностической лаборатории;  магистрант   по направлению подготовки 06.04.01 Биология</p><p>ул. Аккуратова, д. 2, Санкт-Петербург, 197341</p></bio><bio xml:lang="en"><p>Golodyaeva Mariya V. - Biologist,  centralized diagnostic laboratory</p><p>Akkuratova str., 2, Saint Petersburg, 197341</p></bio><email xlink:type="simple">tunicate@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лабинцева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Labintсeva</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лабинцева Елена Владимировна - заведующий централизованной диагностической лабораторией  </p><p>Мурманск</p></bio><bio xml:lang="en"><p>Labintсeva Elena V. - Head of the centralized  diagnostic laboratory </p><p> Murmansk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Государственное областное автономное учреждение здравоохранения «Мурманский областной центр специализированных видов медицинской помощи»;  Федеральное государственное бюджетное учреждение «Национальный медицинский &#13;
исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Murmansk Regional Center for Specialized Types of Medical Care;  Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Государственное областное автономное учреждение здравоохранения «Мурманский областной центр специализированных видов медицинской помощи»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Murmansk Regional Center for Specialized Types of Medical Care</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>21</day><month>09</month><year>2023</year></pub-date><volume>3</volume><issue>4</issue><fpage>59</fpage><lpage>65</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Голодяева М.В., Лабинцева Е.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Голодяева М.В., Лабинцева Е.В.</copyright-holder><copyright-holder xml:lang="en">Golodyaeva M.V., Labintсeva E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://persmed.elpub.ru/jour/article/view/185">https://persmed.elpub.ru/jour/article/view/185</self-uri><abstract><p>Клиническая манифестация COVID-19 варьируется у разных пациентов от бессимптомного течения до тяжелой полиорганной недостаточности. Причины такой вариабельности до конца не известны. Целью данного исследования явился анализ тяжести течения  COVID-19 у госпитализированных пациентов в зависимости от исходной вирусной нагрузки SARS-CoV-2. В исследование были включены 156 пациентов 18 лет и старше. При  проведении исследований методом РВ-ПЦР вирусная нагрузка оценивалась по результатам Ct (пороговое значение цикла амплификации). Результат считался положительным,  когда значения Ct при определении целевых генов были &lt; 40, и отрицательными, когда  Ct были ≥ 40. В ходе исследования были выделены 3 группы по 52 человека в каждой  с различными траекториями течения заболевания: 1 — легкое, 2 — среднетяжелое, 3 —  тяжелое/летальный исход. Значения медианы порога цикла Ct при поступлении пациентов группы 3 в стационар были значительно ниже, что указывает на более высокие  исходные уровни вирусной РНК у пациентов с более тяжелым течением заболевания.  Эта закономерность сохранялась в течение 28-дневного периода, и именно в этой 3 группе на протяжении всего времени определялись более высокие уровни вирусной РНК  по сравнению с другими траекториями течения заболевания. Таким образом, показано  влияние исходной вирусной нагрузки SARS-CoV-2 и ее динамики в период госпитализации на тяжесть течения COVID-19. Данный параметр может выступать прогностическим  маркером для оценки клинического состояния пациентов в ходе лечения.</p></abstract><trans-abstract xml:lang="en"><p>Clinical manifestations of COVID-19 vary in different patients from asymptomatic to severe  multiple organ failure. The aim of this study was to analyze the severity of COVID-19 in  hospitalized patients depending on the initial viral load of SARS-CoV-2. Study included 156  patients 18 years old and more. In the RT-PCR test, viral load was assessed by amplification  cycle threshold Ct. The result was considered positive for Ct values &lt; 40 and negative for  Ct ≥ 40. 3 groups of 52 people each with different trajectories of the course of the disease  were identified: 1 — mild, 2 — moderate, 3 — severe/fatal. The values of the median Ct  cycle threshold upon admission of patients in group 3 to the hospital were significantly lower,  indicating higher initial levels of viral RNA in patients with more severe disease. This pattern  persisted over a 28-day period, and it was in this 3 group that higher levels of viral RNA were  detected throughout the time compared to other disease trajectories. In conclusion, the effect  of the initial SARS-CoV-2 viral load and its dynamics during hospitalization on the severity  of COVID-19 is shown. This parameter can be a prognostic marker for assessing the clinical  condition of patients during treatment.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>вирусная нагрузка</kwd><kwd>исследование методом ПЦР</kwd><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>PCR test</kwd><kwd>SARS-CoV-2</kwd><kwd>viral load</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021;23(1):14. DOI: 10.1208/s12248-020-00532-2.</mixed-citation><mixed-citation xml:lang="en">Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021;23(1):14. DOI: 10.1208/s12248-020-00532-2.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Petrosillo N, Viceconte G, Ergonul O, et al. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729–34. DOI: 10.1016/j.cmi.2020.03.026.</mixed-citation><mixed-citation xml:lang="en">Petrosillo N, Viceconte G, Ergonul O, et al. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729–34. DOI: 10.1016/j.cmi.2020.03.026.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269. DOI: 10.1038/s41586-020-2008-3.</mixed-citation><mixed-citation xml:lang="en">Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269. DOI: 10.1038/s41586-020-2008-3.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mackey K, Ayers CK, Kondo KK, et al. Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths: A Systematic Review. Ann Intern Med. 2021;174(3):362–373. DOI: 10.7326/M20-6306.</mixed-citation><mixed-citation xml:lang="en">Mackey K, Ayers CK, Kondo KK, et al. Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths: A Systematic Review. Ann Intern Med. 2021;174(3):362–373. DOI: 10.7326/M20-6306.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ozonoff A, Schaenman J, Jayavelu ND, et al. Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study. EBioMedicine. 2022;83: 104208. DOI: 10.1016/j.ebiom.2022.104208.</mixed-citation><mixed-citation xml:lang="en">Ozonoff A, Schaenman J, Jayavelu ND, et al. Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study. EBioMedicine. 2022;83: 104208. DOI: 10.1016/j.ebiom.2022.104208.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, et al. Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. Clin Microbiol Rev. 2021;34(3): e00228–20. DOI: 10.1128/CMR.00228-20.</mixed-citation><mixed-citation xml:lang="en">Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, et al. Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. Clin Microbiol Rev. 2021;34(3): e00228–20. DOI: 10.1128/CMR.00228-20.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rai P, Kumar BK, Deekshit VK, et al. Detection technologies and recent developments in the diagnosis of COVID-19 infection. Appl Microbiol Biotechnol. 2021;105(2):441–455. DOI: 10.1007/s00253-020-11061-5.</mixed-citation><mixed-citation xml:lang="en">Rai P, Kumar BK, Deekshit VK, et al. Detection technologies and recent developments in the diagnosis of COVID-19 infection. Appl Microbiol Biotechnol. 2021;105(2):441–455. DOI: 10.1007/s00253-020-11061-5.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Jin X, Duan Y, Bao T, et al. The values of coagulation function in COVID-19 patients. PLoS One. 2020;15(№10): e0241329. DOI: 10.1371/journal.pone.0241329.</mixed-citation><mixed-citation xml:lang="en">Jin X, Duan Y, Bao T, et al. The values of coagulation function in COVID-19 patients. PLoS One. 2020;15(№10): e0241329. DOI: 10.1371/journal.pone.0241329.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">KarimiShahri M, Niazkar HR, Rad F. COVID-19 and hematology findings based on the current evidences: A puzzle with many missing pieces. Int. J. Lab. Hematol. 2021;43(№ 2):160–168. DOI: 10.1111/ijlh.13412.</mixed-citation><mixed-citation xml:lang="en">KarimiShahri M, Niazkar HR, Rad F. COVID-19 and hematology findings based on the current evidences: A puzzle with many missing pieces. Int. J. Lab. Hematol. 2021;43(№ 2):160–168. DOI: 10.1111/ijlh.13412.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Сироткина О.В., Ермаков А.И., Гайковая Л.Б. и др. Микрочастицы клеток крови у больных COVID-19 как маркер активации системы гемостаза. Тромбоз, гемостаз и реология. 2020;4: 35–40. DOI: 10.25555/THR.2020.4.0943.</mixed-citation><mixed-citation xml:lang="en">Sirotkina OV, Ermakov AI, Gaykovaya LB, et al. Microparticles of blood cells in patients with COVID-19 as a marker of hemostasis activation. Tromboz, Gemostaz I Reologiya. 2020; № 4: 35–40. In Russian DOI: 10.25555/THR.2020.4.0943</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Сироткина О.В., Ермаков А.И., Жиленкова Ю.И. и др. Динамика образования микровезикул клеток крови у больных COVID-19 на разных стадиях заболевания. Профилактическая и клиническая медицина. 2021;4(81):68–74. DOI: 10.47843/2074-9120_2021_4_68</mixed-citation><mixed-citation xml:lang="en">Sirotkina OV, Ermakov AI, Zhilenkova YuI, et al. Dynamics of microvesicle formation in blood in patients with COVID-19 at different stages of the disease. Preventive and clinical medicine. 2021;81(№4): 68–74. In Russian DOI: 10.47843/2074-9120_2021_4_68</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Сироткина О.В., Улитина А.С., Кулабухова Д.Г. и др. Корреляция лабораторных маркеров активации системы гемостаза с концентрацией и размером внеклеточных микрочастиц плазмы крови у пациентов с COVID-19. Ученые записки СПбГМУ им. акад. И. П. Павлова. 2022;29(1):28– 36. DOI: 10.24884/1607-4181-2022-29-1-28-36.</mixed-citation><mixed-citation xml:lang="en">Sirotkina OV, Ulitina AS, Kulabukhova DG, et al. Correlation of laboratory markers of hemostatic system activation with concentration and size of plasma extracellular microparticles in patients with COVID-19. The Scientific Notes of the Pavlov University. 2022;29(1):28–36. In Russian DOI: 10.24884/1607-4181-2022-29-1-28-36</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kudryavtsev I, Kalinina O, Bezrukikh V, et al. The Significance of Phenotyping and Quantification of Plasma Extracellular Vesicles Levels Using High-Sensitivity Flow Cytometry during COVID-19 Treatment. Viruses. 2021; 13:767. DOI: 10.3390/v13050767.</mixed-citation><mixed-citation xml:lang="en">Kudryavtsev I, Kalinina O, Bezrukikh V, et al. The Significance of Phenotyping and Quantification of Plasma Extracellular Vesicles Levels Using High-Sensitivity Flow Cytometry during COVID-19 Treatment. Viruses. 2021; 13:767. DOI: 10.3390/v13050767.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Song KH, Kim DM, Lee H, et al. Dynamics of viral load and anti-SARS-CoV-2 antibodies in patients with positive RT-PCR results after recovery from COVID-19. Korean J Intern Med. 2021;36(1):11–14. DOI: 10.3904/kjim.2020.325.</mixed-citation><mixed-citation xml:lang="en">Song KH, Kim DM, Lee H, et al. Dynamics of viral load and anti-SARS-CoV-2 antibodies in patients with positive RT-PCR results after recovery from COVID-19. Korean J Intern Med. 2021;36(1):11–14. DOI: 10.3904/kjim.2020.325.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Serrano-Cumplido A, Ruiz Garcia A, Segura-Fragoso A, et al. Application of the PCR number of cycle threshold value (Ct) in COVID-19. Semergen. 2021;47(5):337–341. In Spanish. DOI: 10.1016/j.semerg.2021.05.003.</mixed-citation><mixed-citation xml:lang="en">Serrano-Cumplido A, Ruiz Garcia A, Segura-Fragoso A, et al. Application of the PCR number of cycle threshold value (Ct) in COVID-19. Semergen. 2021;47(5):337–341. In Spanish. DOI: 10.1016/j.semerg.2021.05.003.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
